OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update

IF 21 1区医学 Q1 ONCOLOGY Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI:10.1016/j.jtho.2024.09.062

D.R. Spigel , M.-J. Ahn , M. Majem , L. Medina Rodríguez , K.H. Lee , E. Carcereny , A.A. Hernández , A. Insa , E.K. Cho , B. Besse , S.Y. Rha , J. Weiss , M. D'Arcangelo , S.-A. Im , S.-W. Kim , B.A. Carneiro , S.M. Gadgeel , P. Mitchell , J.M. Asare , S.D. Gainer , E. Felip

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

OA11.04 Volrustomig + 铂双联化疗 (CTx) 用于一线非小细胞肺癌 (NSCLC)：1b期试验更新

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

期刊最新文献

Erratum to 'Critical Evaluation of Methodologic Approaches in ALK Tyrosine Kinase Inhibitor Research: Addressing Confounding Factors and Statistical Robustness' [Journal of Thoracic Oncology Vol 19 Issue 11 (2024) e64-e65]. PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era. Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial. Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality. DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy.